Objective: To characterize cortico-diaphragmatic pathway involvement in multiple sclerosis (MS) by means of transcranial magnetic stimulation (TMS), and verify its clinical impact.
Introduction
Respiratory muscle weakness in multiple sclerosis (MS) is usually described in the advanced phase of the disease, and accounts for the majority of the fatal events in such patients (Mc Alpine and Compston, 1952) . However, in some cases respiratory involvement may occur earlier in the course of the disease, particularly during relapses (Guthrie et al., 1952) . Respiratory muscle weakness could also contribute to fatigue and increased sense of effort experienced by MS patients.
MS has been the first neurological condition to be studied by both electrical (Cowan et al., 1984) and magnetic (Hess et al., 1986 ) stimulation of the brain.
Several studies have reported prolonged central motor conduction time (CMCT) to different muscle groups in patients with definite MS (Cowan et al., 1984; Mills and Murray, 1985; Ingram et al., 1988) . Recently this technique has been successfully proposed for the non-invasive study of the diaphragm (Dia) (Zifko et al., 1996 , Similowski et al., 1996 and phrenic roots (Chokroverty et al., 1995; Similowski et al., 1997) . There are only few studies which addressed the diaphragmatic impairment in MS by means of transcranial magnetic stimulation (TMS) (Garland et al., 1996; Lagueny et al., 1998) . Garland et al. (1996) found Dia alterations in CMCT in 70% of their cohort, while Lagueny et al. (1998) demonstrated altered MEP latencies from Dia in 41% of the patients studied. The latter claimed also the usefulness of TMS for revealing infraclinical demyelinating lesions on central motor pathways down to the Dia.
However, the evidence of a poor correlation between central motor conduction abnormalities and clinical signs (Hess et al., 1987) questions a reliable prognostic value of this technique to detect respiratory subclinical involvement.
Thus we aimed to characterize the TMS findings,
